CAS 1428569-85-0

Fórmula: C20H22F3N7OS

InChI: InChI=1S/C20H22F3N7OS/c1-29-20(30-7-5-10(21)13(24)6-8-30)14(9-26-29)27-18(31)16-17(25)32-19(28-16)15-11(22)3-2-4-12(15)23/h2-4,9-10,13H,5-8,24-25H2,1H3,(H,27,31)/t10-,13-/m1/s1

Chave InChI: NHXVGMQFCYBLTL-ZWNOBZJWSA-N

SMILES: CN1C(=C(C=N1)NC(=O)C2=C(SC(=N2)C3=C(C=CC=C3F)F)N)N4CC[C@H]([C@@H](CC4)F)N

GDC-0339

CAS: 1428569-85-0

GDC-0339

Fórmula: C₂₀H₂₂F₃N₇OS

Pureza: 99.77%

Peso molecular: 465.5

Ref: 54-PC1032143

GDC-0339

CAS: 1428569-85-0

Fórmula: C₂₀H₂₂F₃N₇OS

Pureza: 99.77%

Peso molecular: 465.4952

Ref: IN-DA009CHZ

GDC-0339

CAS: 1428569-85-0

GDC-0339 is a potent inhibitor of the enzyme farnesyltransferase, which is required for the post-translational modification of proteins. It has been shown to inhibit murine leukemia cells and human cytochrome P450. GDC-0339 is a potent inhibitor of the enzyme farnesyltransferase, which is required for the post-translational modification of proteins. It has been shown to inhibit murine leukemia cells and human cytochrome P450. GDC-0339 inhibits farnesylation by binding to the nicotinamide ring of FTS, preventing its interaction with the protein substrate. The inhibition of this reaction leads to increased levels of cellular prenyl groups and an accumulation of newly synthesized proteins that are not modified by FTS. This drug also has high affinity binding properties and displays constant amplitudes in magnetic resonance analysis (MRA).

Fórmula: C₂₀H₂₂F₃N₇OS

Pureza: Min. 95%

Peso molecular: 465.5 g/mol

Ref: 3D-DHC56985

GDC-0339

CAS: 1428569-85-0

GDC-0339: oral Pim kinase inhibitor for multiple myeloma (Kis: Pim1 - 0.03 nM, Pim2 - 0.1 nM, Pim3 - 0.02 nM), well-tolerated.

Fórmula: C₂₀H₂₂F₃N₇OS

Cor e Forma: Solid

Peso molecular: 465.495

Ref: TM-T15376